{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:46Z","timestamp":1793414146663,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Importance<\/jats:title>\n \n Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the\n BRCA1<\/jats:italic>\n or\n BRCA2<\/jats:italic>\n gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To compare breast cancer mortality rates in women with a\n BRCA1<\/jats:italic>\n or\n BRCA2<\/jats:italic>\n sequence variation who entered an MRI surveillance program with those who did not.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n Women with a\n BRCA1<\/jats:italic>\n or\n BRCA2<\/jats:italic>\n sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Entrance into an MRI surveillance program.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the\n BRCA1<\/jats:italic>\n (n\u2009=\u20092004) or\n BRCA2<\/jats:italic>\n (n\u2009=\u2009484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0.20 (95% CI, 0.10-0.43;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) for women with\n BRCA1<\/jats:italic>\n sequence variations and 0.87 (95% CI, 0.10-17.25;\n P<\/jats:italic>\n \u2009=\u2009.93) for women with\n BRCA2<\/jats:italic>\n sequence variations.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n \n Results of this cohort study suggest that among women with a\n BRCA1<\/jats:italic>\n sequence variation, MRI surveillance was associated with a significant reduction in breast cancer mortality compared with no MRI surveillance. Further studies of women with\n BRCA2<\/jats:italic>\n sequence variations are needed to ascertain these women obtain the same benefits associated with MRI surveillance.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.6944","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:00:41Z","timestamp":1709204441000},"page":"493","source":"Crossref","is-referenced-by-count":80,"title":["MRI Surveillance and Breast Cancer Mortality in Women With\n BRCA1<\/i>\n and\n BRCA2<\/i>\n Sequence Variations"],"prefix":"10.1001","volume":"10","author":[{"given":"Jan","family":"Lubinski","sequence":"first","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Moller","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Peck","sequence":"additional","affiliation":[{"name":"Bhalwani Familial Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Aeilts","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Division of Human Genetics, The Ohio State University Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Eng","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute, Center for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bordeleau","sequence":"additional","affiliation":[{"name":"Department of Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[{"name":"McGill Program in Cancer Genetics, Department of Oncology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[{"name":"Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[{"name":"Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, IRCCS San Gerardo, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ramon y Cajal","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Neuhausen","sequence":"additional","affiliation":[{"name":"Division of Biomarkers of Early Detection and Prevention, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Zakalik","sequence":"additional","affiliation":[{"name":"Cancer Genetics Program, Beaumont Hospital, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Cybulski","sequence":"additional","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Huzarski","sequence":"additional","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Stempa","sequence":"additional","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Dungan","sequence":"additional","affiliation":[{"name":"Northwestern Medical Group, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Cullinane","sequence":"additional","affiliation":[{"name":"Long Beach Memorial Center, Long Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[{"name":"Department of Medicine and Human Genetics, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland"},{"name":"Bloomberg School of Nursing, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Hereditary Breast Cancer Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Sweet","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigha","family":"Senter","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Saal","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Velsher","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Armel","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"McCuaig","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Panchal","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta","family":"Poll","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Lemire","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Serfas","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reilly","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Costalas","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Cohen","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Blum","sequence":"additional","affiliation":[{"name":"for the Hereditary Breast Cancer Clinical Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"coi230090r1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"coi230090r2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"12","key":"coi230090r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104350","article-title":"Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.","volume":"64","author":"Marmolejo","year":"2021","journal-title":"Eur J Med Genet"},{"issue":"2","key":"coi230090r5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/jnci\/djz079","article-title":"Performance measures of magnetic resonance imaging plus mammography in the high risk Ontario Breast Screening Program.","volume":"112","author":"Chiarelli","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"coi230090r6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"coi230090r7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br J Cancer"},{"issue":"9","key":"coi230090r8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.2009.23.0839","article-title":"Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.","volume":"28","author":"Kuhl","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi230090r9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","article-title":"MRI breast screening in high-risk women: cancer detection and survival analysis.","volume":"145","author":"Evans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"coi230090r10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/ijc.v137.7","article-title":"Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).","volume":"137","author":"Saadatmand","year":"2015","journal-title":"Int J Cancer"},{"issue":"8","key":"coi230090r11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi230090r12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-019-05152-9","article-title":"High-risk breast cancer surveillance with MRI: 10-year experience from the German Consortium for Hereditary Breast and Ovarian Cancer.","volume":"175","author":"Bick","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"coi230090r13","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cancers12113479","article-title":"Breast cancer mortality among women with a BRCA1 or BRCA2 mutation in a magnetic resonance imaging plus mammography screening program.","volume":"12","author":"Warner","year":"2020","journal-title":"Cancers (Basel)"},{"key":"coi230090r3","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2023. Published September 7, 2022. Accessed June 24, 2023. https:\/\/cliniclancette.ru\/docs\/genetics_bop-2023.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2815702\/jamaoncology_lubinski_2024_oi_230090_1712704282.69385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:02:27Z","timestamp":1713438147000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2815702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.6944","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}